Becton Dickinson and Company Common Stock (BDX)
Stock · NYSE · Health Care
$191.75as of 10/16/2026
Price chart
Active signals
BDX Signal Track Record
How signals performed across all stocks →What BDX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 29 | -0.3% | 48% | September 8, 2026 |
| 200-Day Moving Average TouchActive now | 26 | -0.9% | 38% | July 10, 2026 |
| Bollinger Band Breakout | 23 | +1.2% | 61% | July 28, 2026 |
| Bollinger Band Breakdown | 20 | +1.1% | 60% | September 8, 2026 |
| Any 20-session window (baseline) | +0.3% | 52% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About BDX
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peri…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 72,000
- Website
- www.bd.com/
Fundamentals
- 1-day range
- $189.51$193.69
- Market cap
- $48.79B
- P/E (trailing)
- 54.13
- P/E (forward)
- 14.52
- EPS (trailing)
- $3.31
- Dividend yield
- 1.59%
- Beta
- 0.24
- Avg. volume
- 1.77M
- Ex-dividend date
- September 9, 2026
- Dividend pay date
- September 30, 2026
How Becton Dickinson and Company Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Nov 25, 2025 · via SEC EDGAR / Finnhub
Forecasts
13 analyst ratings
Becton Dickinson and Company Common Stock Competitors
Chosen by industry and closest market cap.
- BDXBecton Dickinson and Company Common Stock$191.75▼ 1.04%Market cap $48.79BP/E 54.13$127.59$193.07
- MDLNMedline Inc. Class A Common Stock$35.96▼ 1.67%Market cap $45.34BP/E 69.38$31.49$50.88
- RMDResMed Inc. Common Stock$238.97▼ 1.35%Market cap $32.38BP/E 22.23$180.27$277.67
- DXCMDexCom Inc. Common Stock$86.04▼ 1.90%Market cap $31.33BP/E 32.73$54.11$92.59
- BSXBoston Scientific Corporation Common Stock$44.39▲ 0.57%Market cap $71.45BP/E 17.32$41.39$105.65
- WSTWest Pharmaceutical Services Inc. Common Stock$384.02▲ 0.26%Market cap $24.53BP/E 48.71$223.83$386
- BAXBaxter International Inc. Common Stock$25.28▼ 1.86%Market cap $13.96BP/E —$15.73$30
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BDX Becton Dickinson and Company Common Stock | $48.79B | 54.13 | $191.75 | ▼ 1.04% | $127.59$193.07 |
| MDLN Medline Inc. Class A Common Stock | $45.34B | 69.38 | $35.96 | ▼ 1.67% | $31.49$50.88 |
| RMD ResMed Inc. Common Stock | $32.38B | 22.23 | $238.97 | ▼ 1.35% | $180.27$277.67 |
| DXCM DexCom Inc. Common Stock | $31.33B | 32.73 | $86.04 | ▼ 1.90% | $54.11$92.59 |
| BSX Boston Scientific Corporation Common Stock | $71.45B | 17.32 | $44.39 | ▲ 0.57% | $41.39$105.65 |
| WST West Pharmaceutical Services Inc. Common Stock | $24.53B | 48.71 | $384.02 | ▲ 0.26% | $223.83$386 |
| BAX Baxter International Inc. Common Stock | $13.96B | — | $25.28 | ▼ 1.86% | $15.73$30 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Waters Tops Growth Outlook as AI Demand, BD Integration Fuel MomentumYahoo · 9/26/2026
- Best Dividend Kings: September 2026SeekingAlpha · 9/26/2026
- Dividend Champion, Contender, And Challenger Highlights: Week September 27SeekingAlpha · 9/25/2026
- Smoke Evacuation Systems Market Forecasts Growth from $0.20B (2025) to $0.30B by 2031, Profiling CONMED, Medtronic, Stryker & Becton DickinsonYahoo · 9/24/2026
- Waters: Positive Momentum Rides High AgainSeekingAlpha · 9/23/2026
- How Far Can BSX Stock Swing After Losing More Than Half Its Value?Yahoo · 9/22/2026
- Arthur Hu to Join BD as Chief Information and Digital OfficerYahoo · 9/21/2026
- Why Is Becton Dickinson (BDX) Facing Fresh SEC And Litigation Pressure?Yahoo · 9/20/2026
Insider Activity
Insider Actions →- Vitor Roque · September 2, 2026 · Tax Withholding190
- Michael Feld · August 26, 2026 · Sale165 @ $188.49
- Michael Feld · August 20, 2026 · Tax Withholding1.0K
- Thomas E. Polen Jr. · August 13, 2026 · Option Exercise43.3K @ $167.25
- Thomas E. Polen Jr. · August 13, 2026 · Sale4.2K @ $185
- Thomas E. Polen Jr. · August 13, 2026 · Disposition39.1K @ $185
- Roland Goette · August 11, 2026 · Sale2.4K @ $180.84
- Robert Luther Huffines · August 6, 2026 · Grant189 @ $165.62
- Carrie L. Byington · August 6, 2026 · Grant94 @ $165.62
- Michael Feld · July 27, 2026 · Sale75 @ $157.13
- Bilal Muhsin · July 2, 2026 · Tax Withholding1.9K
- Bilal Muhsin · July 1, 2026 · Grant14.3K
- Michael Feld · June 26, 2026 · Sale75 @ $152.8
- Michael David Garrison · June 24, 2026 · Sale1.1K @ $145.66
- Michael David Garrison · June 10, 2026 · Sale1.1K @ $151.48
Institutional Ownership
March 31, 2026
- Total shares held
- 241.36M
- Total value held
- $35.68B
- Institutional holders
- 1454
- Unknown26.15M
- Unknown18.49M
- Unknown13.82M
- Unknown11.93M
- Unknown10.17M
- Unknown9.69M
- Unknown9.10M
- Unknown7.11M
- Unknown6.62M
- Unknown5.36M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BDX Revello Stent Trial Success, Revenue Up 5.4%, Earnings Down 34%
The company announced that its Revello stent achieved strong results in the AGILITY trial for peripheral artery disease patients. Revenue rose 5.4% year‑over‑year, but net earnings fell 34.3%, reflecting higher costs or lower margins. The dividend yield sits at 1.59% and analysts see a target of $194, while the stock trades near the top of its 52‑week range.
BDX Revello Stent Trial Success, Revenue Up 5.4%, Earnings Down 34%. The company announced that its Revello stent achieved strong results in the AGILITY trial for peripheral artery disease patients. Revenue rose 5.4% year‑over‑year, but net earnings fell 34.3%, reflecting higher costs or lower margins. The dividend yield sits at 1.59% and analysts see a target of $194, while the stock trades near the top of its 52‑week range.